Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MiMedx Group Inc.

www.mimedx.com

Latest From MiMedx Group Inc.

Pipeline Watch: Phase III Starts With Murepavadin, CSL112 And Vibegron

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care

The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.

Wound Healing & Tissue Repair Wound Management
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Alynx Co.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MiMedx Group Inc.
  • Senior Management
  • David Coles, Interim CEO
    Edward J Borkowski, Interim CFO
    Thomas J Koob, PhD, CSO
    David H Mason, MD, CMO
    John D Harris, SVP, Mktg. & Bus. Dev.
  • Contact Info
  • MiMedx Group Inc.
    Phone: (888) 543-1917
    1775 West Oak Commons Ct. NE
    Marietta, GA 30062
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register